SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jaybe8/5/2016 9:44:34 PM
   of 4474
 
Moffit Center in Tampa finds preclinical superiority for pona in RET+ NSCLC...

As we await the results of two IST's for pona in RET+ NSCLC (UColo at 45mg & MGH at 30mg), evidence accumulates for its potential.

"Among cabozantinib, lenvatinib, ponatinib, and vandetanib, our data show that ponatinib is the most potent inhibitor of RET PTK. Treatment of lung tumors induced by KIF5B-RET in the transgenic animals resulted in tumor regression. Thus, ponatinib is an effective drug for treating KIF5B-RET-associated lung adenocarcinoma in this genetically engineered mouse model and is predicted to show anti-tumor efficacy in RET fusion lung adenocarcinoma patients. While the gatekeeper RETV804L and RETV804M mutations are less sensitive to ponatinib than the wildtype RET, ponatinib remains the most potent inhibitor. Thus, ponatinib appears to be the drug of choice for treating RET fusion-associated lung adenocarcinoma."

mct.aacrjournals.org



Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News